Key takeaways:

• Danegaptide could be an oral therapy for patients with moderate to severe nonproliferative diabetic retinopathy.
• The treatment was well tolerated in a phase 1b trial, with fundraising underway for phase 2.

Danegaptide, a potential oral therapy for nonproliferative diabetic retinopathy, is advancing to a phase 2 trial after showing a favorable safety profile in a phase 1b trial, according to a press release from Breye Therapeutics.

The therapy could be used to treat patients with earlier or moderate stages of the disease, for whom traditional intravitreal injections are typically too burdensome, Ulrik Mouritzen, MD, CEO of Breye Therapeutics, told Healio.

“These patients are not complaining about vision loss yet, and so only a noninvasive oral therapy will be able to treat them,” Mouritzen said.

Read more: https://www.healio.com/news/optometry/20250722/oral-danegaptide-for-diabetic-retinopathy-successfully-completes-phase-1b-trial?utm_source=selligent&utm_medium=email&utm_campaign=20250722PCON&utm_content=20250722PCON

Source: Healio